Coronavirus Update: Will Dexamethasone Breakthrough Make Remdesivir Irrelevant?
Plus AZ's Vaccine May Only Protect For One Year
The RECOVERY trial has produced clear results for the cheap steroid treatment dexamethasone. What does it mean for Gilead's antiviral remdesivir?
You may also be interested in...
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.
A third set of authoritative results from UK trial ruled out use of AbbVie's HIV combination, plus Bharat Biotech to launch Phase I vaccine trials.